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Abstract: The prediction of drug–target interactions (DTIs) via computational technology plays
a crucial role in reducing the experimental cost. A variety of state-of-the-art methods have been
proposed to improve the accuracy of DTI predictions. In this paper, we propose a kind of drug–target
interactions predictor adopting multi-scale discrete wavelet transform and network features (named
as DAWN) in order to solve the DTIs prediction problem. We encode the drug molecule by a
substructure fingerprint with a dictionary of substructure patterns. Simultaneously, we apply the
discrete wavelet transform (DWT) to extract features from target sequences. Then, we concatenate
and normalize the target, drug, and network features to construct feature vectors. The prediction
model is obtained by feeding these feature vectors into the support vector machine (SVM) classifier.
Extensive experimental results show that the prediction ability of DAWN has a compatibility among
other DTI prediction schemes. The prediction areas under the precision–recall curves (AUPRs) of
four datasets are 0.895 (Enzyme), 0.921 (Ion Channel), 0.786 (guanosine-binding protein coupled
receptor, GPCR), and 0.603 (Nuclear Receptor), respectively.
Keywords: drug–target interactions; discrete wavelet transform; network property; support
vector machine
1. Introduction
Although the PubChem database [1] has stored millions of chemical compounds, the number of
compounds having target protein information are limited. Drug discovery (finding new drug–target
interactions, DTIs) requires much more cost and time via biochemical experiments. Hence, some
efficient computational methods for predicting potential DTIs are used to cover the shortage of
traditional experimental methods. There are three categories of the DTIs prediction approaches:
molecular docking, matrix-based, and feature vector-based methods. Cheng et al. [2] and
Rarey et al. [3] developed molecular docking methods, which were based on the crystal structure
of the target binding site (3D structures). Docking simulations quantitatively estimate the maximal
affinity achievable by a drug-like molecule, and these calculated values correlate with drug discovery
outcomes. However, docking simulations depend on the spatial structure of targets and are usually
time-consuming because of the screening technique. In contrast to docking methods, the other two
kinds of computational methods (matrix-based and feature vector-based methods) can achieve the
large-scale prediction of DTIs.
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Compared with molecular docking, matrix-based methods of chemical structure similarity are
more popular. Many matrix-based approaches are becoming popular in the area of DTI predicition.
The bipartite graph learning (BGL) [4] model was firstly proposed by Yamanishi et al. They developed
a new supervised method to infer unknown DTIs by integrating chemical space and genomic space into
a unified space. Bleakley and Yamanishi et al. [5] raised the bipartite local model (BLM) to solve the
DTI prediction problem in chemical and genomic spaces, and applied the bipartite model to transform
prediction into a binary classification [5]. Mei et al. [6] improved the BLM with neighbor-based
interaction-profile inferring (BLM-NII). The NII strategy inferred label information or training data
from neighbors when there was no training data readily available from the query compound/protein
itself. Laarhoven et al. designed kernel regularized least squares (RLS), in which they defined Gaussian
interaction profile (GIP) kernels on the profiles of drugs and targets to predict DTIs [7]. Xia et al.
raised Laplacian regularized least square based on interaction network (NetLapRLS) [8] to improve
the prediction performance of RLS. Zheng et al. built a DTI predictor with collaborative matrix
factorization (CMF) [9], which can incorporate multiple types of similarities from drugs and those
from targets at once. Laarhoven et al. [10] also proposed weighted nearest neighbor with Gaussian
interaction profile kernels (WNN-GIP) to predict DTIs. The WNN constructed an interaction score
profile for a new drug compound using chemical and interaction information about known compounds
in the dataset. Another matrix factorization-based method—kernelized Bayesian matrix factorization
with twin kernels (KBMF2K) [11]—was proposed by Gönen, M. The novelty of KBMF2K came from
the joint Bayesian formulation of projecting drug compounds and target proteins into a unified
subspace using the similarities and estimating the interaction network in that subspace. Neighborhood
regularized logistic matrix factorization (NRLMF) was raised by Liu et al. [12]. NRLMF focused on
modeling the probability that a drug would interact with a target by logistic matrix factorization,
where the properties of drugs and targets were represented by drug-specific and target-specific latent
vectors, respectively. Nevertheless, the drawback of pairwise kernel method is the high computational
complexity on the occasion of a large numbers of samples. In addition, matrix-based methods did
not consider the physical and chemical properties of the target protein. These properties reflect some
particular relationship between targets and the molecular structure of drugs.
To handle the above problem, other machine learning approaches of feature vector-based method
was raised. Cao et al. firstly proposed several works to predict DTIs via drug (molecular fingerprint),
target (sequence descriptors), and network information [13,14]. They used composition (C), transition
(T), and distribution (D) and Molecular ACCess System (MACCS) fingerprint to describe target
sequence and drug molecule, respectively. The above features were fed into random forest (RF) to
detect DTIs.
In this article, we propose a new DTI predictor based on signal compression technology. The target
sequence can be regarded as biomolecule signal of a cell. To further extract effective features from the
target sequence, we utilize discrete wavelet transform (DWT) as a spectral analysis tool to compress the
signal of the target sequence. According to Heisenberg’s uncertainty principle, the velocity and location
of moving quanta cannot be determined at the same time. Similarly, in a time–frequency coordinate
system, the frequency and location of a signal cannot be determined at the same time. Wavelet
transform can be based on the scale of the transformation and offset in different frequency bands,
given different resolution. This is an effective scenario in practice. We also use MACCS fingerprint
to describe the drug. Further more, network feature provides the relationship between drug–target
pairs. Many models (e.g., BLM, BLM-NII, NetLapRLS, CMF, KBMF2K, NRLMF, and Cao’s work [14])
were built with network information. Therefore, our feature contains sequence (DWT feature), drug
(MACCS feature), and network (net feature). Moreover, we combine the above three types of features
with support vector machine (SVM) and feature selection (FS) to develop a predictor of DTIs. We
evaluate our method on four benchmark datasets including Enzyme, Ion Channel, guanosine-binding
protein coupled receptor (GPCR), and Nuclear receptor. The result shows that our method achieves
better prediction performance than outstanding approaches.
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2. Results
We evaluated our method (DAWN) on balanced DTI datasets, described by Cao’s work [14].
We analyzed the performance of features (including MACCS, DWT, and net feature). Then, we
compared DAWN with other outstanding methods, including BLM [5], RLS [7], BGL [4], NetLapRLS [8],
and Cao’s work [14]. In addition, we also tested DAWN on imbalanced DTI datasets, compared with
NetLapRLS [8], BLM-NII [6], CMF [9], WNN-GIP [10], KBMF2K [11], and NRLMF [12]. We found that
DAWN achieved better values of AUCs.
2.1. Dataset
To evaluate the performance and scalability of our method, we adopted enzyme, ion channels,
GPCR, and nuclear receptors used by Yamanishi et al. [4] as the gold standard datasets. These datasets
come from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [15]. The information
of drug–target interactions comes from KEGG BRITE [15], BRENDA [16], Super Target [17], and
DrugBank databases [18]. Table 1 presents some quantitative descriptors about the golden datasets,
including the number of drugs (n), number of targets (m), number of interactions, and ratio of n to m.
Table 1. Statistics of DTI datasets [4].
Drugs (n) Targets (m) Interactions Ratio (n/m)
Enzyme 445 664 2926 0.67
IC 210 204 1476 1.03
GPCR 223 95 635 2.35
Nuclear receptors 54 26 90 2.08
IC: ion channel; GPCR: guanosine-binding protein coupled receptor.
2.1.1. Balanced Dataset
In Cao’s study [14], all real drug–target interaction pairs were used as the positive samples.
For negative examples, they selected random, unknown interacting pairs from these drug and
protein molecules. DAWN was tested on Cao’s four balanced benchmark datasets (including Enzyme,
Ion channels, GPCRs, and Nuclear receptors).
2.1.2. Imbalanced Dataset
The gold standard datasets only contain positive examples (interaction pairs). Hence,
non-interaction drug–target pairs are considered as negative examples. Because the number of
non-interaction pairs is larger than interaction pairs, the ratio between majority and minority examples
is much greater than 1.
2.2. Evaluation Measurements
Three parameters were adopted as criteria: overall prediction accuracy (ACC), sensitivity (SN),
and specificity (Spec).
• Accuracy:
ACC =
TP+ TN
TP+ FP+ TN + FN
(1)
• Sensitivity or Recall:
SN =
TP
TP+ FN
(2)
• Specificity:
Spec =
TN
TN + FP
(3)
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TP represents the number of positive samples predicted correctly. Similarly, we have TN, FP and
FN, which represent the number of negative samples predicted correctly, the number of negative
samples predicted as positive, and the positive samples predicted as negative, respectively.
In signal detection theory, a receiver operating characteristic (ROC), or simply ROC curve, is a
graphical plot illustrating the performance of a binary classifier system as its varied discrimination
threshold. A ROC curve can be used to illustrate the relation between sensitivity and specificity.
Area under the precision–recall curve (PRC) (AUPR) is an average of the precision weighted
by a given threshold probability. We employed both ROC and the area under the precision–recall
curve (PRC), because the representation of PRC is more effective than ROC on highly imbalanced or
skewed datasets. Area under the ROC curve (AUC) and AUPR can quantitatively describe sensitivity
against specificity and precision against recall, respectively.
2.3. Experimental Results on Balanced Datasets
2.3.1. Performance Analysis of Feature
In order to analyze the performance of MACCS, DWT, and net features, we tested these
features on four balanced datasets (each set contains 10 balanced subsets) through five-fold
cross-validation. Results of DWT + MACCS, DWT + MACCS (with FS), DWT + NET + MACCS,
and DWT + NET + MACCS (with FS) are shown in Table 2. Because the datasets are balanced,
the evaluation of ACC or AUC can measure overall performance. DWT + NET + MACCS (with
FS) had the best performance of ACC on Enzyme (0.938), IC (0.943), GPCR (0.890), and Nuclear
receptor (0.860), respectively. The performance (AUC) of DWT + NET + MACCS (Enzyme: 0.977,
IC: 0.978, GPCR: 0.934, Nuclear receptor: 0.866) was better than DWT + MACCS (Enzyme: 0.925, IC:
0.929, GPCR: 0.872, Nuclear receptor: 0.816). The feature DWT + NET + MACCS indeed improved
the prediction performance by adding network information. In addition, the performance (AUC) of
DWT + NET + MACCS (with FS) (Enzyme: 0.980, IC: 0.983, GPCR: 0.950, Nuclear receptor: 0.931)
was better than DWT + NET + MACCS (without FS) (Enzyme: 0.977, IC: 0.978, GPCR: 0.934,
Nuclear receptor: 0.866).
Table 2. Comparison of the prediction performance between different features on balanced datasets.
Dataset Feature ACC Sn SP AUC
Enzyme
DWT + MACCS 0.867 ± 0.002 0.861 ± 0.004 0.873 ± 0.003 0.925 ± 0.003
DWT + MACCS (FS) 0.895 ± 0.001 0.901 ± 0.003 0.889 ± 0.003 0.949 ± 0.001
DWT + NET + MACCS 0.932 ± 0.003 0.933 ± 0.002 0.933 ± 0.002 0.977 ± 0.002
DWT + NET + MACCS (FS) 0.938 ± 0.002 0.938 ± 0.002 0.939 ± 0.004 0.980 ± 0.001
IC
DWT + MACCS 0.864 ± 0.003 0.868 ± 0.004 0.861 ± 0.005 0.929 ± 0.004
DWT + MACCS (FS) 0.879 ± 0.004 0.891 ± 0.004 0.866 ± 0.007 0.935 ± 0.003
DWT + NET + MACCS 0.940 ± 0.004 0.932 ± 0.005 0.943 ± 0.006 0.978 ± 0.003
DWT + NET + MACCS (FS) 0.943 ± 0.002 0.938 ± 0.003 0.949 ± 0.003 0.983 ± 0.001
GPCR
DWT + MACCS 0.826 ± 0.005 0.831 ± 0.003 0.822 ± 0.007 0.872 ± 0.004
DWT + MACCS (FS) 0.836 ± 0.006 0.846 ± 0.007 0.827 ± 0.009 0.892 ± 0.005
DWT + NET + MACCS 0.872 ± 0.004 0.872 ± 0.005 0.872 ± 0.003 0.934 ± 0.005
DWT + NET + MACCS (FS) 0.890 ± 0.005 0.888 ± 0.009 0.891 ± 0.011 0.950 ± 0.002
Nuclear receptor
DWT + MACCS 0.750 ± 0.011 0.619 ± 0.013 0.879 ± 0.021 0.816 ± 0.015
DWT + MACCS (FS) 0.791 ± 0.017 0.790 ± 0.018 0.793 ± 0.036 0.850 ± 0.016
DWT + NET + MACCS 0.805 ± 0.021 0.767 ± 0.017 0.837 ± 0.013 0.866 ± 0.011
DWT + NET + MACCS (FS) 0.860 ± 0.009 0.855 ± 0.013 0.867 ± 0.024 0.931 ± 0.009
DWT: discrete wavelet transform; FS: feature selection; NET: network features; MACCS: drug features of
molecular access system.
It is clear that FS plays a key role in elevating the prediction of our method. The FS can enhance
generalization by reducing the overfitting. Obviously, the performance of DWT + NET + MACCS
(with FS) can be seen from Figures 1 and 2. Network topology can be a useful supplement to improve
prediction effect.
Int. J. Mol. Sci. 2017, 18, 1781 5 of 15
1-Specificity
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Se
ns
itiv
ity
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
bio+chem+net feature
bio+chem feature
(a)
1-Specificity
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Se
ns
itiv
ity
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
bio+chem+net feature
bio+chem feature
(b)
1-Specificity
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Se
ns
itiv
ity
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
bio+chem+net feature
bio+chem feature
(c)
1-Specificity
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Se
ns
itiv
ity
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
bio+chem+net feature
bio+chem feature
(d)
Figure 1. The area under the Receiver Operating characteristic Curve (ROC) values obtained on
balanced datasets (with FS). The blue curve is the combined feature of MACCS (chem), DWT (bio), and
net. The red curve is the combined feature of MACCS (chem) and DWT (bio); (a) Enzyme’s ROC curve
with network feature; (b) IC ’s ROC curve with network feature; (c) GPCR’s ROC curve with network
feature; (d) Nuclear receptor’s ROC curve with network feature.
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Figure 2. The area under the precision–recall (PR) curve (AUPR) values obtained on balanced datasets
(with FS). The blue curve is the combined feature of MACCS (chem), DWT (bio), and net. The red
curve is the combined feature of MACCS (chem) and DWT (bio); (a) Enzyme’s PR curve with network
feature; (b) IC’s PR curve with network feature; (c) GPCR’s PR curve with network feature; (d) Nuclear
receptor’s PR curve with network feature.
2.3.2. Comparing with Existing Methods
On the balanced datasets [14], we compare DAWN with other common methods by five-fold cross
validation. These methods contain BLM [5], RLS [7], BGL [4], NetLapRLS [8] and Cao’s work [14].
The detailed results are listed in Table 3. DAWN achieved the best values of AUCs on Enzyme (0.980)
and Nuclear receptor (0.931), respectively. Although the AUC value of DAWN on Ion channel and
GPCR datasets were not higher than Cao’s work [14] and BLM, we still have a competitive prediction rate.
Recapitulating about the aforementioned description, DAWN has a competitive ability among these works.
Table 3. The mean AUC values of five methods on balanced datasets.
Methods Enzyme IC GPCR Nuclear Receptor
Cao’s work [14] 0.979 0.987 0.951 0.924
BGL 0.904 0.851 0.899 0.843
BLM 0.976 0.973 0.955 0.881
NetLapRLS 0.956 0.947 0.931 0.856
RLS 0.978 0.984 0.954 0.922
DAWN (our method) 0.980 0.983 0.950 0.931
Results excerpted from [14]. The best results in each column are in bold faces. BGL: bipartite graph learning;
BLM: bipartite local model; NetLapRLS: Laplacian regularized least square based on interaction network;
RLS: regularized least square. DAWN: prediction of Drug–tArget interactions based on multi-scale discrete
Wavelet transform and Network features.
2.4. Experimental Results on Imbalanced Datasets
In order to highlight the advantage of our method, we also tested DAWN on the imbalanced
datasets of DTIs by 10-fold cross validation. DAWN was compared with NetLapRLS [8], BLM-NII [6],
CMF [9], WNN-GIP [10], KBMF2K [11], and NRLMF [12]. The detailed results are listed in Table 4.
Because the datasets are imbalanced, the evaluation of AUC and AUPR were both used to measure
overall performance. DAWN achieved average AUCs of 0.981, 0.990, 0.952, and 0.906, and the AUPR
values of DAWN were 0.895, 0.921, 0.786, and 0.603 on Enzyme, Ion channel, GPCR, and Nuclear
receptor, respectively. The AUC value of DAWN on the Enzyme dataset was 0.981 and AUPR was 0.895,
and only the NRLMF (AUC: 0.987, AUPR: 0.892) method was comparable. On Ion channel and GPCR
datasets, we also had best or second-best results. For AUPR value on Nuclear receptor, NRLMF was
higher than DAWN. The Nuclear receptor dataset is smaller than the other three datasets. The size of
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the dataset might be a reason for DAWN’s performance. Therefore, the DAWN method that adopted the
mean of DWT was not as effective as larger datasets. However, among methods in Table 4, none could
give markedly higher prediction performance on all four datasets in both AUC and AUPR. Therefore,
it is fair to claim that our strategy has comparable performance. Further, Figures 3 and 4 show the
curves of AUC and AUPR on imbalanced datasets through 10-fold cross validation. Related datasets,
codes, and figures of our algorithm are available at https://github.com/6gbluewind/DTI_DWT.
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Figure 3. ROC of imbalanced datasets by 10-fold cross-validation; (a) Enzyme’s ROC curve with
network feature; (b) IC’s ROC curve with network feature; (c) GPCR’s ROC curve with network feature;
(d) Nuclear receptor’s ROC curve with network feature.
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Figure 4. AUPR of imbalanced datasets by 10-fold cross-validation. (a) Enzyme’s PR curve with
network feature. (b) IC’s PR curve with network feature. (c) GPCR’s PR curve with network feature.
(d) Nuclear receptor’s PR curve with network feature.
Table 4. Overall AUC and AUPR values of different methods on imbalanced dataset for four species.
Evaluation Method Enzyme Ion Channel GPCR Nuclear Receptor
AUC
NetLapRLS 0.972 ± 0.002 0.969 ± 0.003 0.915 ± 0.006 0.850 ± 0.021
BLM-NII 0.978 ± 0.002 0.981 ± 0.002 0.950 ± 0.006 0.905 ± 0.023
WNN-GIP 0.964 ± 0.003 0.959 ± 0.003 0.944 ± 0.005 0.901 ± 0.017
KBMF2K 0.905 ± 0.003 0.961 ± 0.003 0.926 ± 0.006 0.877 ± 0.023
CMF 0.969 ± 0.002 0.981 ± 0.002 0.940 ± 0.007 0.864 ± 0.026
NRLMF 0.987 ± 0.001 0.989 ± 0.001 0.969 ± 0.004 0.950 ± 0.011
DAWN 0.981 ± 0.004 0.990 ± 0.014 0.952 ± 0.009 0.906 ± 0.067
AUPR
NetLapRLS 0.789 ± 0.005 0.837 ± 0.009 0.616 ± 0.015 0.465 ± 0.044
BLM-NII 0.752 ± 0.011 0.821 ± 0.012 0.524 ± 0.024 0.659 ± 0.039
WNN-GIP 0.706 ± 0.017 0.717 ± 0.020 0.520 ± 0.021 0.589 ± 0.034
KBMF2K 0.654 ± 0.008 0.771 ± 0.009 0.578 ± 0.018 0.534 ± 0.050
CMF 0.877 ± 0.005 0.923 ± 0.006 0.745 ± 0.013 0.584 ± 0.042
NRLMF 0.892 ± 0.006 0.906 ± 0.008 0.749 ± 0.015 0.728 ± 0.041
DAWN 0.895 ± 0.011 0.921 ± 0.036 0.786 ± 0.023 0.603 ± 0.087
Results excerpted from [12]. The best results in each column are in bold faces and the second best
results are underlined. BLM-NII: improved BLM with neighbor-based interaction-profile inferring; CMF:
collaborative matrix factorization; KBMF2K: kernelized Bayesian matrix factorization with twin kernels;
NRLMF: neighborhood regularized logistic matrix factorization; WNN-GIP: weighted nearest neighbor
with Gaussian interaction profile kernels.
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2.5. Predicting New DTIs
In this experiment, the balanced DTIs were set as training data sets. We ranked the remaining
non-interacting pairs and selected the top five non-interacting pairs as predicted interactions.
We utilized four well-known biological databases (including ChEMBL (C) [19], DrugBank (D) [18],
KEGG (K) [15] and Matador (M) [20]) as references to verify whether or not the predicted new DTIs are
true. The predicted novel interactions by DAWN can be ranked based on the interaction probabilities,
which are shown in Table 5. The potential DTIs may be present in one or several databases. For
example, the secondly ranked DTI of GPCR (D00563: hsa3269) belongs to DrugBank and Matador
databases. In addition, the DTI databases (the above four databases) are still being updated, and the
accuracy of identifying new DTIs by DAWN may be increased.
Table 5. Top five new DTIs predicted by DAWN on four data sets.
Dataset Rank Drug Target Databases
Enzyme
1 D00545 hsa1571
2 D03365 hsa1571
3 D00437 hsa1559 M
4 D00546 hsa1571
5 D00184 hsa5478 D
Ion channel
1 D00542 hsa6262
2 D00542 hsa6263 M
3 D00349 hsa6263
4 D00477 hsa6336 C
5 D01448 hsa3782
GPCR
1 D01051 hsa3269
2 D00563 hsa3269 D, M
3 D00563 hsa1812 D
4 D00715 hsa1129 D, K
5 D00563 hsa1129
Nuclear receptor
1 D01689 hsa5241
2 D01115 hsa5241
3 D00443 hsa5241 D
4 D00443 hsa367 D
5 D00187 hsa2099
C: ChEMBL; D: DrugBank; K: KEGG; M: Matador.
3. Discussion
In this paper, we proposed a new DTIs predictor based on signal compression technology.
We encoded the drug molecule by a substructure fingerprint with a dictionary of substructure patterns.
Moreover, we applied the DWT to extract features from target sequences. At last, we concatenated the
target, drug, and network features to construct predictive model of DTIs.
To evaluate the performance of our method, the DTIs model was compared to other state-of-the-art
DTIs prediction methods on four benchmark datasets. DAWN achieved average AUCs of 0.981, 0.990,
0.952, and 0.906, and the AUPR values of DAWN were 0.895, 0.921, 0.786, and 0.603 on Enzyme, Ion
channel, GPCR, and Nuclear receptor, respectively. Although our result using feature selection could
be a kind of ameliorated prediction, the imbalanced problem of DTIs prediction is not solved very well.
SVM is poor on imbalanced data. The AUPR value of DAWN is low on the Nuclear receptor dataset.
4. Materials and Methods
To predict DTIs by machine learning methods, one challenge is to extract effective features from
the target protein, drug, and the relationship between drug–target pairs. Considering that DTIs
depend on the molecular properties of the drug and the physicochemical properties of target, we use
MACCS fingerprints (Open Babel 2.4.0 Released, OpenEye Scientific Software, Inc., Santa Fe, New
Mexico, United States) to represent the drug, and extract biological features from the target via DWT.
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In addition, the net feature describes the topology information of the DTIs network. We utilize the
above features to train the SVM predictor (LIBSVM Version 3.22, National Taiwan University, Taiwan,
China) for detecting DTIs.
4.1. Molecular Substructure Fingerprint of Drug
To encode the chemical structure of the drug, we utilize MACCS fingerprints with 166 common
chemical substructures. These substructures are defined in the Molecular Design Limited (MDL)
system, which can be found from OpenBabel (http://openbabel.org). The MACCS feature is encoded
by a binary bits vector, which shows the presence (1) or absence (0) of some specific substructures in a
molecule. Please refer to the relevant literature [13,14] for details.
4.2. Biological Feature of Target
4.2.1. Six Physicochemical Properties of Amino Acids
The target sequence can be denoted by seq = {r1, r2, · · · , ri, · · · , rL}, where 1 ≤ i ≤ L. ri is the
i-th residue of sequence seq, and L is the length of sequence seq. In addition, for ease of calculation
about feature representation, we select six kinds of physicochemical properties for 20 amino acid types
as original target features [21–24]. More specifically, they are hydrophobicity (H), volumes of side chains
of amino acids (VSC), polarity (P1), polarizability (P2), solvent-accessible surface area (SASA) and net charge
index of side chains (NCISC), respectively. Values of all kinds of amino acid are shown in Table 6.
Table 6. Six physicochemical properties of 20 amino acid types.
Amino Acid H VSC P1 P2 SASA NCISC
A 0.62 27.5 8.1 0.046 1.181 0.007187
C 0.29 44.6 5.5 0.128 1.461 −0.03661
D −0.9 40 13 0.105 1.587 −0.02382
E −0.74 62 12.3 0.151 1.862 0.006802
F 1.19 115.5 5.2 0.29 2.228 0.037552
G 0.48 0 9 0 0.881 0.179052
H −0.4 79 10.4 0.23 2.025 −0.01069
I 1.38 93.5 5.2 0.186 1.81 0.021631
K −1.5 100 11.3 0.219 2.258 0.017708
L 1.06 93.5 4.9 0.186 1.931 0.051672
M 0.64 94.1 5.7 0.221 2.034 0.002683
N −0.78 58.7 11.6 0.134 1.655 0.005392
P 0.12 41.9 8 0.131 1.468 0.239531
Q −0.85 80.7 10.5 0.18 1.932 0.049211
R −2.53 105 10.5 0.291 2.56 0.043587
S −0.18 29.3 9.2 0.062 1.298 0.004627
T −0.05 51.3 8.6 0.108 1.525 0.003352
V 1.08 71.5 5.9 0.14 1.645 0.057004
W 0.81 145.5 5.4 0.409 2.663 0.037977
Y 0.26 117.3 6.2 0.298 2.368 0.023599
H: hydrophobicity; VSC: volumes of side chains of amino acids; P1: polarity; P2: polarizability; SASA:
solvent-accessible surface area; NCISC: net charge index of side chains.
For the sake of facilitating the dealing with the datasets, the amino acid residues are translated
and normalized according to Equation (4).
P′ij =
Pij − Pj
Sj
(j = 1, 2, . . . , 6; i = 1, 2, . . . , 20) (4)
where Pi,j and Pj indicate the value of the j-th descriptor of amino acid type i and the mean of 20 amino
acid types of descriptor value j, respectively, standard deviation (SD) corresponding to Sj.
Each target sequence can be translated into six vectors with each amino acid represented by
normalized values of six descriptors. Thus, the seq can be represented as physicochemical matrix
X = [x1, ..., xch, ..., x6],X ∈ RL×6, xch ∈ RL×1, ch = 1, 2, ..., 6.
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4.2.2. Discrete Wavelet Transform
Discrete wavelet transform (DWT) with its inversion formula was established by physical intuition
and practical experience of signal processing [25].
If a signal or a function can be represented as Equation (5), then the signal or function has a linear
decomposition. If the formula of expansion is unique, then the set of expansion can be said as a group
of basis. If this group of basis is orthogonal or represented as Equation (6), then the coefficient can be
computed by inner product as Equation (7).
f (t) =∑
`
a`ψ`(t), (5)
(ψk(t),ψ`(t)) =
∫
ψk(t)ψ`(t)dt = 0, k 6= `, (6)
ak = ( f (t),ψk(t)) =
∫
f (t)ψk(t)dt, (7)
where ` and k are the finite or infinite integer indexes, a` and ak are the real coefficients of the expansion,
and ψ`(t) and ψk(t) are the set of real functions.
For wavelet expansion, we can construct a system with two parameters, then the formula can be
transferred as Equation (8):
f (t) =∑
k
∑
j
aj,kψj,k(t), (8)
where j and k are integer index, and ψj,k(t) is wavelet function, which generally forms a group of
orthogonal basis.
The expansion coefficient set aj,k is known as the discrete wavelet transform (DWT) of f (t).
Nanni et al. proposed an efficient algorithm to perform DWT by assuming that the discrete signal f (t)
is xch(n).
yl,high,ch(n) =
L
∑
k=1
[xch(k) · h(2n− k)] (9a)
yl,low,ch(n) =
L
∑
k=1
[xch(k) · g(2n− k)] (9b)
where h and g refer to high-pass filter and low-pass filter, L is the length of discrete signal, yl,low,ch(n)
is the approximate coefficient (low-frequency components) of the signal, l(l = 1, 2, 3, 4) is the
decomposition level of DWT, ch(ch = 1, 2, 3, 4, 5, 6) is the physicochemical index, and yl,low,ch(n)
is the detailed coefficient (high-frequency components).
DWT can decompose discrete sequences into high- and low-frequency coefficients.
Nanni et al. [26] substituted each amino acid of the protein sequence with a physicochemical property.
Then, the protein sequence was encoded as a numerical sequence. DWT compresses discrete sequence
and removes noise from the origin sequence. Different decomposition scales with discrete wavelet
have different results for representing the sequence of the target protein. They used 4-level DWT and
calculated the maximum, minimum, mean, and standard deviation values of different scales (four
levels of both low- and high-frequency coefficients). In addition, high-frequency components are more
noisy while low-frequency components are more critical. Therefore, they extracted the beginning of the
first five Discrete Cosine Transform (DCT) coefficients from the approximation coefficients. We utilize
Nanni’s method to describe the sequence of the target protein. The schematic diagram of a 4-level
DWT is shown in Figure 5.
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4.3. Drug–Target Associations from Network
State-of-the-art works such as BLM [5], BLM-NII [6], NetLapRLS [8], CMF [9], KBMF2K [11],
NRLMF [12], and Cao’s work [14] used DTI network topology information to improve the prediction
performance. Therefore, we also consider utilizing net feature to build a DTI predictor.
The DTI network can be conveniently regarded as a bipartite graph. In the network, each drug
is associated with nt targets, and each target is associated with nd drugs. Excluding target Tj itself,
we make a binary vector of all other known targets of Di in the bipartite network, as well as a
separate list of targets not known to be targeted by Di. Known and unknown targets are labeled by
1 and 0, respectively. For drug Di, we get (nt − 1)-dimensional binary vector. Similarly, we also get
(nd − 1)-dimensional binary vector of target Tj. Thus, we can get a [(nd − 1) + (nt − 1)]-dimensional
vector for describing net feature.
4.4. Feature Selection and Training SVMModel
Not all features are useful for DTIs prediction. Therefore, we apply support vector machine
recursive feature elimination and correlation bias reduction (SVM-RFE+CBR) [27,28] to select the
important features of DTIs. The SVM-RFE+CBR can estimate the score of importance for each
dimensional feature. We rank these features (including MACCS feature, DWT feature, and net
feature) by the scores in descending order. Then, we select an optimal feature subset in top k ranked
manner to predict DTIs.
Support vector machine (SVM) was originally developed by Vapnik [29] and coworkers, and
has shown a promising capability to solve a number of chemical or biological classification problems.
SVM and other machine learning algorithms (e.g., random forest, RF, k-nearest neighbor, kNN, etc.)
are widely used in computational biology [30–33]. SVM performs classification tasks by constructing a
hyperplane in a multidimensional space to differentiate two classes with a maximum margin. The input
data of SVM is defined as {xi, yi}, i = 1, 2, ..., N, feature vector xi ∈ Rn and labels yi ∈ {+1,−1}.
The classification decision function implemented by SVM is shown as Equation (10).
f (x) = sgn{
N
∑
i=1
yiαi · K(x, xi) + b} (10)
where the coefficient αi is obtained by solving a convex quadratic programming problem, and K(x, xi)
is called a kernel function.
Here, we focus on choosing a radial basis function (RBF) kernel [34], because it not only has
better boundary response but can also make most high-dimensional data approximate a Gaussian-like
distribution. The architecture of our proposed method is shown in Figures 6 and 7.
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Figure 7. Flow chart. DWT: discrete wavelet transform; DCT: discrete cosine transform; Std: standard
deviation; SVM: support vector machine.
5. Conclusions
In this paper, we present a DTI prediction method by using multi-scale discrete wavelet transform
and network features. We employ a DWT algorithm to extract target features, and combine them with
drug fingerprint and network feature. Our method can achieve satisfactory prediction performances,
and our prediction can be a kind of ameliorated prediction by comparing with other existing methods
after feature selection. However, the imbalanced problem of DTIs prediction is not solved very well.
SVM is poor on imbalanced data. The AUPR value of DAWN is low on the Nuclear receptor dataset.
The prediction accuracy may be further enhanced with the further expansion of more refined
representation of the structural and physicochemical properties or a better machine learning model
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(such as sparse representation and gradient boosting decision tree) for predicting drug–target
interactions. In the future, we will build the classification by the strategy of bootstrap sampling
and weighting sub-classifiers.
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